Today: 7 February 2026
Subscribe
Browse Category

NYSE:HBAN News 4 February 2026 - 6 February 2026

Cadence Bank stock price: CADE frozen after Huntington takeover, focus shifts to HBAN

Cadence Bank stock price: CADE frozen after Huntington takeover, focus shifts to HBAN

Cadence Bank shares remain halted after closing at $42.11 on Jan. 30, as each share converts to 2.475 shares of Huntington Bancshares under a finalized merger. Huntington traded at $19.02 premarket Friday. Huntington will keep all Cadence branches open and aims to finish customer account conversions by mid-2026. Investors await Huntington’s February 10 appearance at a UBS conference.
6 February 2026
··
Cadence Bank stock (CADE) is suspended after Huntington merger — what happens to shares now

Cadence Bank stock (CADE) is suspended after Huntington merger — what happens to shares now

Cadence Bank shares were halted on the NYSE after its acquisition by Huntington Bancshares, with the last close at $42.11 on Jan. 30. Cadence shareholders will receive 2.475 Huntington shares per Cadence share, plus cash for fractional shares. Huntington now controls $279 billion in assets and will keep Cadence’s 390 branches open. Investors await integration updates at a Feb. 10 conference.
4 February 2026
··

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop